Pharmafile Logo
Pharmafocus logo
Advanced Search

Lixisenatide

Showing 6 posts of 6 posts found.

sanofi_hq__boetie_hall

Sanofi gets FDA approval for type-2 diabetes treatment Adlyxin

July 28, 2016
Research and Development, Sales and Marketing FDA, Lixisenatide, Lyxumia, Sanofi, adlyxin, approval, diabetes, type 2, type-2, zealand

Sanofi has announced that the US Food and Drug Administration (FDA) has approved Adlyxin (lixisenatide), which is a once-daily mealtime …

News
diabetes_injection

Sanofi’s LixiLan meets target in Phase III diabetes trial

September 16, 2015
Research and Development Lantus, LixiLan, Lixisenatide, Lxyumia, Sanofi, diabetes, insulin glargine, metformin, type 2 diabetes

Sanofi’s Phase III clinical trial of its Lixilan treatment has achieved its primary endpoint in patients with type 2 diabetes, …

News
Sanofi image

Sanofi diabetes drug fails to show cardio disease benefit

March 19, 2015
Research and Development, Sales and Marketing ACS, Lixisenatide, Lyxumia, Sanofi, cardio, diabetes

A Phase IIIb study of Sanofi’s diabetes drug lixisenatide has shown it is no better or worse than a placebo …

News
Sanofi image

Sanofi withdraws lixisenatide US application

September 12, 2013
Sales and Marketing FDA, Lixisenatide, Sanofi, diabetes, elixa

In a blow to its diabetes pipeline, Sanofi has withdrawn a new drug application (NDA) for lixisenatide in the US …

News

Lixisenatide shaping up to rival Victoza

September 22, 2010
Research and Development Lixisenatide, Sanofi-Aventis, diabetes

Data for Sanofi-Aventis’ injectable lixisenatide suggests it could rival Novo Nordisk’s drug Victoza.Lixisenatide is a once-daily GLP-1 receptor agonist, and …

News

Lixisenatide scores in phase III trial

April 15, 2010
Research and Development GLP-1, Lixisenatide, diabetes

Sanofi-Aventis’ novel, once-daily diabetes treatment lixisenatide has successfully met its phase III glucose blood level and glycaemic control endpoints. The …

News
The Gateway to Local Adoption Series

Latest content

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026